RT Journal Article
SR Electronic
T1 Efficacy Estimates for Various COVID-19 Vaccines: What we Know from the Literature and Reports
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.20.21257461
DO 10.1101/2021.05.20.21257461
A1 Julia Shapiro
A1 Natalie E. Dean
A1 Zachary J. Madewell
A1 Yang Yang
A1 M.Elizabeth Halloran
A1 Ira Longini
YR 2021
UL http://medrxiv.org/content/early/2021/06/18/2021.05.20.21257461.abstract
AB In this report, we provide summary estimates, from publications and reports, of vaccine efficacy (VE) for the COVID-19 vaccines that are being rolled out on a global scale. We find that, on average, the efficacy against any disease with infection is 85% (95% CI: 71 - 93%) after a fully course of vaccination. The VE against severe disease, hospitalization or death averages close to 100%. The average VE against infection, regardless of symptoms, is 84% (95% CI: 70 - 91%). We also find that the average VE against transmission to others for infected vaccinated people is 48% (95% CI: 45 - 52%). Finally, we prove summary estimates of the VE against any disease with infection for some of the variants of concern (VOC). The average VE for the VOC γ (P1) is 61% (95% CI: 43 - 73%). The average VE for the VOC α (B.1.1.7), β (B.1.351), and δ (B.1.617.2) after dose 1 are 48% (95% CI: 44 - 51%), 35% (95% CI: -11 - 62%), and 33% (95% CI: 21 - 43%), respectively. The average VE for the VOC α (B.1.1.7), β (B.1.351), and δ (B.1.617.2) after dose 2 are 85% (95% CI: 25 - 97%), 57% (95% CI: 14 - 78%), and 78% (95% CI: 28 - 93%), respectively.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partially funded by NIH grants R01AI139761 and R56AI148284.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All relevant ethical guidelines have been followed. Only summary data have been used. These summary data are completely deidentified All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe agree to make data used to compile this paper available